ProShares Ultra NASDAQ Biotechnology
BIB
BIB
32 hedge funds and large institutions have $26.1M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.73% more ownership
Funds ownership: 6.11% → 6.84% (+0.73%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less call options, than puts
Call options by funds: $16.6M | Put options by funds: $18.3M
Holders
32
Holding in Top 10
1
Calls
$16.6M
Puts
$18.3M
Top Buyers
| 1 | +$2.43M | |
| 2 | +$1.03M | |
| 3 | +$1.01M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$779K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$485K |
Top Sellers
| 1 | -$4.05M | |
| 2 | -$1.09M | |
| 3 | -$721K | |
| 4 |
BA
BKS Advisors
Southfield,
Michigan
|
-$470K |
| 5 |
BGC
Blue Granite Capital
Charleston,
South Carolina
|
-$145K |